Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024)
Sunshine Biopharma (SBFM) posted Non-Current Deferred Tax Liability of $141396.0 for Q4 2024, up 190.17% on a QoQ basis from $48729.0 in Q3 2024, and up 161.37% year-over-year from $54097.0 in Q1 2024.
Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024) Analysis & Trends
Sunshine Biopharma's Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $141396.0 for Q4 2024.
- Quarterly Non-Current Deferred Tax Liability rose 161.37% year-over-year to $141396.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $141396.0 (up 161.37% YoY) and the FY2024 annual result came in at $141396.0, up 161.37% from the prior year.
- Non-Current Deferred Tax Liability was $141396.0 for Q4 2024 at Sunshine Biopharma, up from $48729.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $141396.0 in Q4 2024 and bottomed at $43032.0 in Q4 2022.
- A 3-year average of $57089.8 and a median of $48729.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Peak annual rise in Non-Current Deferred Tax Liability reached 161.37% in 2024, while the deepest fall reached 13.24% in 2024.
- Sunshine Biopharma's Non-Current Deferred Tax Liability stood at $43032.0 in 2022, then grew by 25.71% to $54097.0 in 2023, then jumped by 161.37% to $141396.0 in 2024.
- Business Quant data shows SBFM's Non-Current Deferred Tax Liability at $141396.0 in Q4 2024, $48729.0 in Q3 2024, and $48729.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 141,396.00 |
| Dec 31, 2024 | 141,396.00 |
| Sep 30, 2024 | 48,729.00 |
| Sep 30, 2024 | 48,729.00 |
| Jun 30, 2024 | 48,729.00 |
| Jun 30, 2024 | 48,729.00 |
| Mar 31, 2024 | 48,729.00 |
| Mar 31, 2024 | 48,729.00 |
| Dec 31, 2023 | 54,097.00 |
| Dec 31, 2023 | 54,097.00 |
| Sep 30, 2023 | 43,032.00 |
| Sep 30, 2023 | 43,032.00 |
| Jun 30, 2023 | 43,032.00 |
| Jun 30, 2023 | 43,032.00 |
| Mar 31, 2023 | 43,032.00 |
| Mar 31, 2023 | 43,032.00 |
| Dec 31, 2022 | 43,032.00 |
| Dec 31, 2022 | 43,032.00 |